Newsfeeds - Spark Newswire

1 minute read

Palisade Bio Granted U.S. Patent Titled ‘Administration of serine protease inhibitors to the stomach’

Today, 9:23 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11439611.PN.&OS=PN/1143961

PALI

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 19, 2022

By Benzinga Insights

Today, 9:23 PM

Upgrades

AIRC

1 minute read

Maxim Group Downgrades Palisade Bio to Hold

By Benzinga Newsdesk

Today, 9:23 PM

Maxim Group analyst Naz Rahman downgrades Palisade Bio (NASDAQ:PALI) from Buy to Hold.

PALI

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 9:23 PM

AGLE

2 minute read

Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 9:23 PM

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat…

BLUE

3 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 9:23 PM

AKU

4 minute read

Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 9:23 PM

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle platform.

1 minute read

Palisade Bio Shares Drop Following Commencement Of Late-Stage Return Of Bowel Study

By Ragothaman Srinivasan

Today, 9:23 PM

Palisade Bio (NASDAQ: PALI) has dosed first patient in its Phase 3 study evaluating lead asset LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.

PALI

1 minute read

Palisade Bio Q2 EPS $(0.12) Up From $(4.10) YoY

By Benzinga Newsdesk

Today, 9:23 PM

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.12) per share. This is a 97.07 percent increase over losses of $(4.10) per share from the same period last year.

PALI

8 minute read

Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday

By Lisa Levin

Today, 9:23 PM

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.

ACRX